Could you please tell me how many patients you have treated for Triple Negative breast cancer in the last 3 months with the following systemic anti-cancer therapies:
a) Anthracycline (e.g. doxorubicin) as single agent
b) Atezolizumab + nab-paclitaxel or paclitaxel
c) Capecitabine as a single agent
d) Eribulin as a single agent or in combination
e) PARP inhibitor (e.g. Olaparib)
f) Pembrolizumab + chemotherapy
g) Platinum (e.g. carboplatin, cisplatin) as a single agent
h) Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
i) Taxane + Anthracycline based combinations
j) Vinorelbine as a single agent
k) Other active systemic anti-cancer therapy

Triple-Negative (ER negative, PR negative and HER2 negative) breast cancer. 110322.docx